A NEW COMBINATION OF IDARUBICIN, ETOPOSIDE AND CYTARABINE IN UNTREATED ACUTE NONLYMPHOBLASTIC LEUKEMIA

被引：9

作者：

CARELLA, AM ^{[1
]}

GAOZZA, E ^{[1
]}

PIATTI, G ^{[1
]}

NATI, S ^{[1
]}

PUNGOLINO, E ^{[1
]}

SANTINI, G ^{[1
]}

GIORDANO, D ^{[1
]}

CERRI, R ^{[1
]}

RISSO, M ^{[1
]}

ROSSI, E ^{[1
]}

SPRIANO, M ^{[1
]}

CONGIU, A ^{[1
]}

CARLIER, P ^{[1
]}

RAFFO, MR ^{[1
]}

DAMAGIO, E ^{[1
]}

BACIGALUPO, A ^{[1
]}

MARMONT, AM ^{[1
]}

机构：

[1] OSPED SAN MARTINO GENOVA,BONE MARROW TRANSPLANTAT UNIT,GENOA,ITALY

来源：

LEUKEMIA & LYMPHOMA | 1990年 / 2卷 / 05期

关键词：

ANLL; Arac; Ldarubicin; Leukemia; VP; 16;

D O I：

10.3109/10428199009106467

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Sixty-seven unselected adult patients with untreated acute non lymphotblastic leukemia (ANLL) ranging in age from 15 to 80 years received a new induction regimen consisting of Idarubicin, Etoposide and Cytarabine. Patients who entered complete remission (CR) were then allocated to 4 courses of post remission intensification. After this, patients under 50 years of age with a compatible donor were given allogeneic bone marrow transplantation (BMT) or autologous BMT (ABMT) in those without an HLA-compatible donor; the remainder, older than 50, did not receive further therapy. Fifty-six of 67 patients (83.5% achieved CR (02.5% in young and 70.3% in old patients) and 40 (71 % after the first course. Seven patients (of whom, 6 were > 50 years) died in aplasia during the induction phase and four additional patients (all elderly) died during post-remission intensification without recurrent disease. Subsequently, the younger patients received transplants (BMT: 4 pts; ABMT: 10 pts). Twelve: of the 52 (23% who survived post remission intensification (BMT: 1; ABMT: 4; others: 7) are disease free survivors 9-67 months (median, 32 months) after achieving CR. In conclusion, this intensive chemotherapy regimen is highly effective both in young and odder patients but the post-remission intensification may be too aggressive for elderly patients. © 1990 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted.

引用

页码：317 / 322

页数：6

共 36 条

[1] Weinstein Mayer H.J., Rosenthal R.J.D., Coral F.S., Camitta R.M., Gelber R.D., Chemotherapy for acute myelogenous leukemia in children and adults: VAPA update, Blood, 62, pp. 315-319, (1983)
[2] Baehner Bernstein R.L., Sather I.D.H., Et al., Contrasting benefits of two maintenance programs following identical induction in children with acute nonlymphocytic leukemia: a report from the Children's Cancer Study Group, Cancer Treat Rep, 68, pp. 1269-1272, (1984)
[3] Creutzig Ritter U., Riehm J.H., Et al., Contrasting benefits of two maintenance programs following identical induction in children with acute nonlymphocytic leukemia: a report from the Children's (Cancer Study Group, Cancer Treat Rep, 68, pp. 1269-1271, (1984)
[4] Dahl Kalwnsky E.V.D.K., Mirro J., Look at a comparison of cytokinetically based versus intensive chemotherapy for childhood acute myelogenous leukemia, Hematology and Blood Transfusion, 30, pp. 83-87, (1987)
[5] Amadori Ceci S., Comelli A.A., Treatment of acute myelogenous leukemia in children. Results of the Italian Cooperative Study AIEOP/LAM 8204, J. Clin. Oncol, 5, pp. 1356-1363, (1987)
[6] Grier Gelber H.E., Camitta R.D.B.M., Et al., Prognostic factors in (childhood acute myelogenous leukemia, J. Clin Oncol, 5, pp. 1026-1032, (1987)
[7] Woods Ruymann W.G., Lampkin F.B.B.C., Et al., Aggressive intensification treatment may abrogate the need for maintenance therapy in children with acute non-lymphocytic leukemia, Blood, 70, (1987)
[8] Berman Arlin E., Gaynor Z.A., Miller J., Gee W., Kempin T., Mertelsmann J., Andreef R., Reich M., Nahmias L.N., Clarkson B., (Comparative trial of Cytarabine and Thioguanine in Combination with Amsacrine: or Daunorubicin in patients with untreated acute non lymphocytic leukemia: Results of the L-16M Protocol, Leukemia, 3, pp. 115-121, (1989)
[9] Sauter Berchtold C., Fopp W.M., Et al., Acute myelowgenous leukemia: maintenance chemotherapy after early consolidation treatments does not prolong survival, Lancet, pp. 379-382, (1984)
[10] Cassileth Begg P.A., Bennet C.B.J.M., Et al., randomized study of the efficacy of consolidation therapy in acute nonlymphocytic leukemia, Blood, 63, pp. 843-847, (1984)

← 1 2 3 4 →